Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors

Radiotherapy and Oncology

Volumn 96, Issue 3, 2010, Pages 339-346

  Lambrecht, Maarten ^a   Haustermans, Karin ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Gastro intestinal tract; PET; Radiotherapy; Target volume

Indexed keywords

3' FLUOROTHYMIDINE F 18; CARBON 11; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18;

ANORECTAL CANCER; ANUS CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; GASTROINTESTINAL TUMOR; HUMAN; IMAGE QUALITY; INTESTINE INJURY; KIDNEY INJURY; LIVER CELL CARCINOMA; LIVER METASTASIS; MULTIMODALITY CANCER THERAPY; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION INJURY; RECTUM CANCER; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPINAL CORD INJURY; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME; VALIDATION PROCESS;

FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77956169381     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.07.019     Document Type: Review

References (87)

1. E. Kapiteijn, A.M. Marijnen, and I.D. Nagtegaal Preoperative radiotherapy combined with Total mesorectal excision for resectable rectal cancer N Engl J Med 345 2001 638 646
2. C. Mariette, G. Piessen, and J.P. Triboulet Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities Lancet Oncol 8 2007 545 553
3. B. Berger, and B. Claus Evidence-based radiation oncology: Oesophagus Radiother Oncol 92 2009 276 290
4. V. Valentini, F. Cellini, and B. Minsk Survival after radiotherapy in gastric cancer: Systematic review and meta-analysis Radiother Oncol 92 2009 176 183
5. A. Sultana, C. Tudur Smith, and D. Cunningham Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy Br J Cancer 96 2007 1183 1190
6. J. Bjerregaard, M. Mortensen, and M. Jensen Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer Radiother Oncol 92 2009 226 230
7. H. Abdel-Nabi, R.J. Doerr, and D.M. Lamonica Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxuglucose whole body PET: Correlation with histopathologic and CT findings Radiology 206 1998 755 760
8. I. Kantorova, L. Lipska, and O. Belohlavek Routine (18)F-FDG PET preoperative staging of colorectal cancer: Comparison with conventional staging and ist impact on treatment decision making J Nucl Med 44 2003 1784 1788
9. S. Bipat, M.S. van Leeuwen, and E.F. Comans Colorectal liver metastases: CT, MR imaging and PET for diagnosis-meta-analysis Radiology 224 2005 748 756
10. R.H. Huebner, K.C. Park, and J.E. Shepherd A Meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer J Nucl Med 41 2000 1177 1189
11. F.L. Flanagan, F. Dehdashti, and B.A. Siegel Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography AJR Am J roentgenol 168 1997 417 424
12. T. Lerut, P. Flamen, and N. Ectors Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy Ann Surg 232 2000 743 752
13. P. Flamen, A. Lerut, and E. Van Cutsem The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer J Thorac Cardiovasc Surg 120 2000 1085 1092
14. M.H. Janssen, M.C. Ollers, and R.G. Riedl Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging Int J Radiat Oncol Biol Phys 77 2010 392 399
15. H.J. Aerts, P. Lambin, and D. De Ruysscher FDG for dose painting: a rational choice Radiother Oncol 2010 [Epub ahead of print]
16. L.B. Been, A.J.H. Suurmeijer, P. Cobben, P. Jager, H.J. Hoekstra, and P.H. Elsinga [18F]FLT-PET in oncology: current status and and opportunities Eur J Nuc Med Mol Imaging 31 2004 1659 1672
17. W.J. Koh, J.S. Rasey, and M.L. Evans Imaging of hypoxia in human tumors with 18F-fluoromisonidazole Int J Radiat Oncol Biol Phys 41 1992 31 39
18. M. MacManus, U. Nestle, and K.E. Rosenzweig Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007 Radiother Oncol 91 2009 85 94
19. J.R. Siewert, and K. Ott Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 17 2006 38 44
20. M. Mamede, G. El Fakhri, P. Abrue-e Lima, W. Gandler, V. Nosé, and V.H. Gerbaudo Preoperative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation Ann Nucl Med 21 2007 553 562
21. 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the Esophagus Int J Radiat Oncol Biol Phys 73 2009 136 141
22. W. Yu, X.L. Fu, and Y.J. Zhang GTV spatial conformity between different delineations methods by 18FDG-PET/CT and pathology in esophageal cancer Radiother Oncol 93 2009 441 446
23. J.F. Daisne, M. Sibomana, and A. Bol Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: Influence of reconstruction algorithms Radiother Oncol 69 2003 247 250
24. S. Roels, P. Slagmolen, and J. Nuyts Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls Int J Radiat Oncol Biol Phys 75 2009 782 790
25. O. Vrieze, K. Haustermans, and W. De Wever Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 73 2004 269 275
26. S. Shimizu, M. Hosokawa, K. Itoh, M. Fujita, H. Takahashi, and H. Shirato Can hybrid FDG-PET/CT detect subclinical lymph node metastasis of esophageal cancer appropriately and contribute to radiation treatment planning? A comparison of image-based an pathological findings Int J Clin Oncol 14 2009 421 425
27. T. Leong, C. Everitt, and K. Yuen A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer Radiother Oncol 78 2006 254 261
28. 18F-fluorodeoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma Int J Radiat Oncol Biol Phys 63 2005 340 345
29. C.T. Muijs, L.M. Schreurs, and D.M. Busz Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer Radiother Oncol 93 2009 447 453
30. J.R. Siewert, and H.J. Stein Classification of adenocarcinoma of the oesophagogastric junction Br J Surg 85 1998 1457 1459
31. D.G. Power, and J.V. Reynolds Localized adenocarcinoma of the esophagogastric junction - Is there a standard of care? Cancer Treat Rev 2010 [Epub ahead of print]
32. O. Matzinger, E. Gerber, and Z. Bernstein EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach Radiother Oncol 92 2009 164 175
33. W.A. Weber, K. Ott, and K. Becker Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 2001 3058 3065
34. K. Ott, W.A. Weber, and F. Lordick Metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the esophagogastri junction J Clin Oncol 24 2006 4692 4698
35. F. Lordick, K. Ott, and B.J. Krause PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial Lancet Oncol 8 2007 797 805
36. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind TNM Classification of Malignant Tumours 7th ed. 2009 Wiley New York
37. D. Han, J. Yu, and Y. Yu Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus Int J Radiat Oncol Biol Phys 15 2010 1235 1241
38. J.S. Macdonald, S.R. Smalley, and J. Benedetti Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 2001 725 730
39. M. Yun, J.S. Lim, and S.H. Noh Lymph node staging of gastric cancer using 18F-FDG PET: A comparison study with CT J Nucl Med 46 2005 1582 1588
40. K. Mukai, Y. Ishida, K. Okajima, H. Isozaki, T. Morimoto, and S. Nishiyama Usefulness of preoperative FDG-PET for detection of gastric cancer Gastric cancer 9 2006 192 196
41. A. Stahl, K. Ott, and W.A. Weber FDG-PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings Eur J Nucl Med Mol Imaging 30 2003 288 295
42. Q.-M. Yang, T. Kawamura, and H. Itoh Is PET-CT suitable for predicting lymph node status for gastric cancer? Hepatogastroenterology 33 2008 782 785
43. K. Ott, U. Fink, and K. Becker Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial J Clin Oncol 21 2003 4604 4610
44. F. Di Fabio, C. Pinto, and F.L. Rojas Llimpe The predictive value of 18F-FDG-PET early evalution in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab Gastric Cancer 10 2007 221 227
45. K. Hermann, K. Ott, and A.K. Buck Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis J Nucl Med 48 2007 1945 1950
46. C. Moertel, S. Frytak, and R. Hahn Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderated dose radiation (4000 rads)5-fluorouracil and high dose radiation 5-fluorouracil: the gastrointestinal tumor study group Cancer 48 1981 1705 1710
47. F. Huguet, N. Girard, and C. Seblain-El Guerche Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review J Clin Oncol 27 2009 2269 2277
48. K.E. Rusthoven, B.D. Kavanagh, and H. Cardenes Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases J Clin Oncol 27 2009 1572 1578
49. A.C. Koong, E. Christofferson, and Q.T. Le Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 63 2005 230 323
50. D.T. Chang, D. Schellenberg, and J. Shen Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas Cancer 115 2009 665 672
51. D. Schellenberg, A. Quon, and A.Y. Minn (18)Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy Int J Radiat Oncol Bio Phys 77 2010 1420 1425
52. D. Schellenberg, K.A. Goodman, and Florence Lee Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 72 2008 678 686
53. 18FDG-PET/CT for image-Guided and intensity-modulated Radiotherapy J Nucl Med 50 2009 1655 1665
54. A. Quon, S.T. Chang, and F. Chin Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer Eur J Nucl Med Mol Imaging 35 2008 527 531
55. L.A. Dawson, C.J. McGinn, R.K. Tenhaken, S. Walker, W. Ensminger, and T.S. Lawrence Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies J Clin Oncol 18 2000 2210 2218
56. J. Wulf, M. Guckenberger, and U. Haedinger Stereotactic radiotherapy of primary liver cancer and hepatic metastases Acta Oncol 45 2006 897 906
57. R.V. Tse, M. Hawkins, and G. Lockwood Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma J Clin Oncol 26 2008 657 664
58. J. Ricke, P. Wust, and A. Stohlmann CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: Phase I-II results of a novel technique Int J Radiat Oncol Biol Phys 58 2004 1496 1505
59. M.T. Lee, J.J. Kim, and R. Dinniwell Phase I study of individualized stereotactic body radiotherapy of liver metastasis J Clin Oncol 27 2009 1585 1591
60. M.A. Khan, C.S. Combs, and E.M. Brunt Positron emission tomography scanning in the evaluation of hepatocellular carcinoma J Hepatology 32 2000 792 797
61. L.B. Jeng, S.P. Changlai, Y.Y. Shen, C.C. Lin, C.H. Tsai, and C.H. Tsai Limited value of 18F-2 deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers Hepatogastroenterology 50 2003 2154 2156
62. S.A. Teefey, C.C. Hildeboldt, and F. Dehdashti Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imagin US and PET Radiology 226 2003 533 542
63. 11C-Acetate PET imaging in hepatocellular carcinoma and other liver masses J Nucl Med 44 2003 213 221
64. 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma J Nucl Med 49 2008 1912 1921
65. 18[F]FDG PET/CT Eur J Nucl Med Mol Imaging 33 2006 1285 1289
66. M.A. Adson, J.A. van Heerden, and M.H. Adson Resection of hepatic metastases from colorectal cancer Arch Surg 119 1984 647 651
67. O.A. Ogunbiyi, F.L. Flanagan, and F. Dehdashti Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography Ann Surg Oncol 4 1997 613 620
68. P. Flamen, S. Stroobants, and E. Van Cutsm Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-deoxy-d-glucose in recurrent colorectal cancer J Clin Oncol 17 1997 894 901
69. F.G. Fernandez, J.A. Drebin, and D.C. Linehan Five-Year Survival After Resection of Hepatic Metastases From Colorectal Cancer in Patients Screened by Positron Emission Tomography With F-18 Fluorodeoxyglucose (FDG-PET) Ann Surg 240 2004 438 450
70. I.G. Steffen, P. Wust, and R. Ruehl Value of combined PET/CT for radiation planning in CT-Guided percutaneous interstitial high-dose-rate single-fraction brachytherapy for colorectal liver metastases Int J Radiat Oncol Biol Phys 77 2010 1178 1185
71. T. Akhurst, T.J. Kates, and M. Mazumdar Recent chemotherapy reduces the sensitivity of 18F Fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases J Clin Oncol 23 2005 8713 8716
72. R. Sauer, H. Becker, W. Hohenberger German Rectal Cancer Study Group Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
73. S. Roels, W. Duthoy, K. Haustermans, F. Penninckx, V. Vandecaveye, and T. Boterberg Definition and delineation of the clinical target volume for rectal cancer Int J Radiat Oncol Biol Phys 65 2006 1129 1142
74. A. Habr-Gama, R.O. Perez, and W. Nadalin Operative versus non operative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results Ann Surg 240 2004 711 717
75. K. Bujko, P. Richter, and M. Kołodziejczyk Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders Radiother Oncol 92 2009 195 201
76. B. Engels, M. De Ridder, and K. Tournel Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel Int J Radiat Oncol Biol Phys 5 2009 1476 1480
77. S. Roels, P. Slagmolen, and J. Nuyts Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? Acta Oncol 47 2008 1237 1248
78. I.F. Ciernik, M. Huser, C. Burger, J. Bernard Davis, and G. Szekely Automated functional image-guided radiation treatment planning for rectal cancer Int J Radiat Oncol Biol Phys 62 2005 893 900
79. S. Roels, K. Haustermans, and V. Gregoir In regard to Ciernik et al. Automated functional image-guided radiation treatment planning for rectal cancer Int J Radiat Oncol Biol Phys 64 2006 1611 1615
80. International Commission on Radiation Units and Measurements, ICRU Report 50: dose specification for reporting external beam therapy with photons and electrons, ICRU, Bethesda, MD; 1993.
81. D.A. Patel, S.T. Chang, and K.A. Goodman Impact of Integrated PET/CT on variability of target volume delineation in rectal cancer Technol Cancer Res Treat 6 2007 31 36
82. N.D. Nigro, V.K. Vaitkevicius, and B. Consisine Jr Combined therapy for cancer of the anal canal: a preliminary report Dis colon Rectum 17 1974 354 356
83. H. Bartelink, F. Roelofsen, and F. Eschwege Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal cooperative Groups J Clin Oncol 15 1997 2040 2049
84. S.E. Cotter, P.W. Grigsby, and B.A. Siegel FDG-PET/CT in the evaluation of anal carcinoma Int J Radiat Oncol Biol Phys 65 2006 720 725
85. B.T. Nguyen, D.L. Joon, and V. Khoo Assessing the impact of FDG-PET in the management of anal cancer Radiother Oncol 87 2008 376 382
86. J.K. Schwarz, B.A. Siegel, and F. Dehdashti Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer Int J Radiat Oncol BIol Phys 71 2008 180 186
87. S.K. Mai, G. Welzel, B. Hermann, F. Wenz, U. Haberkorn, and D.J. Dinter Can the radiation dose to CT-enlarged buy FDG-PET-negative inguinal lymph nodes in anal cancer be reduced? Strahlenther Onkol 185 2009 254 259